螞蟻集團:去年研發投入234.5億人幣創新高
螞蟻集團發布《2024年可持續發展報告》,提及過去三年來集團每年的研發投入超過營收的10%,2024年投入的234.5億元人民幣創下歷史新高。全球共持有授權專利23,550件,發明專利佔比達95.6%。
迄今為止,集團已開源2,000多個代碼倉庫,支援11,000名開發者共建的開源社區。
同時,集團集團將AI能力融入醫療、金融、生活等場景,推出一系列AI應用服務,自上線以來,服務的用戶累計超過1.3億,其中有43%來自於三線及以下城市。
依托人工智能、區塊鏈、分布式數據庫與安全科技等核心技術,螞蟻集團已累計助力超過24,000家企業提升營運管理效率,推動數智化轉型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.